Yang Kevin T, Wang Fei, Lu Xiaohan, Peng Kexin, Yang Tianxin, David Symons J
Department of Internal Medicine, University of Utah, Salt Lake City, Utah.
College of Health, University of Utah, Salt Lake City, Utah.
Physiol Rep. 2017 Nov;5(21). doi: 10.14814/phy2.13410.
Earlier we reported that the recombinant soluble (pro) renin receptor sPRR-His upregulates renal aquoporin-2 (AQP2) expression, and attenuates polyuria associated with nephrogenic diabetes insipidus (NDI) induced by vasopressin type 2 receptor (V2R) antagonism. Patients that receive lithium therapy develop polyuria associated NDI that might be secondary to downregulation of renal AQP2. We hypothesized that sPRR-His attenuates indices of NDI associated with lithium treatment. Eight-week-old male C57/BL6 mice consumed chow supplemented with LiCl (40 mmol/kg diets) for 14 days. For the last 7 days mice received either sPRR-His [30 g/(kg day), i.v.; sPRR] or vehicle (Veh) via minipump. Control (Con) mice consumed standard chow for 14 days. Compared to Con mice, 14-d LiCl treatment elevated water intake and urine volume, and decreased urine osmolality, regardless of sPRR-His or Veh administration. These data indicate that sPRR-His treatment does not attenuate indices of NDI evoked by lithium. Unexpectedly, epididymal fat mass was lower, adipocyte UCP1 mRNA and protein expression were higher, and multilocular lipid morphology was enhanced, in LiCl-fed mice treated with sPRR-His versus vehicle. The beiging of white adipose tissue is a novel metabolic benefit of manipulating the sPRR in the context of lithium-induced NDI.
我们之前报道过,重组可溶性(原)肾素受体sPRR-His可上调肾水通道蛋白2(AQP2)的表达,并减轻与2型血管加压素受体(V2R)拮抗诱导的肾性尿崩症(NDI)相关的多尿。接受锂治疗的患者会出现与NDI相关的多尿,这可能继发于肾AQP2的下调。我们假设sPRR-His可减轻与锂治疗相关的NDI指标。8周龄雄性C57/BL6小鼠食用添加LiCl(40 mmol/kg饮食)的饲料14天。在最后7天,小鼠通过微型泵接受sPRR-His [30 μg/(kg·天),静脉注射;sPRR]或溶剂(Veh)。对照(Con)小鼠食用标准饲料14天。与Con小鼠相比,无论给予sPRR-His还是Veh,14天的LiCl治疗均增加了水摄入量和尿量,并降低了尿渗透压。这些数据表明,sPRR-His治疗并不能减轻锂诱发的NDI指标。出乎意料的是,与接受溶剂的小鼠相比,接受sPRR-His治疗的LiCl喂养小鼠的附睾脂肪量更低,脂肪细胞UCP1 mRNA和蛋白表达更高,且多房脂质形态增强。在锂诱导的NDI背景下,白色脂肪组织的米色化是操纵sPRR的一种新的代谢益处。